Search the Newsreel

Amneal (NASDAQ:AMRX) Beats Expectations in Strong Q2 CY2026, Stock Jumps 15.9%

Amneal (NASDAQ:AMRX) Beats Expectations in Strong Q2 CY2026, Stock Jumps 15.9% Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) reported Q2 CY2026 results topping the market's revenue expectations , with sales up 9.9% year on year to $796.2 million. The company's full-year revenue guidance of $3.15 billion …

Amneal: Q2 Earnings Snapshot

Amneal Pharmaceuticals (AMRX) Wins FDA Nod For Iohexol, Is The Upside Already Priced In?

Amneal Pharmaceuticals (AMRX) recently received FDA approval for additional strengths and vial sizes of its iohexol injection, boosting its product portfolio and contributing to strong share price momentum. While analysts consider the stock about 5% overvalued with a fair value of $18.25, Simply Wall …

Amneal Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:AMRX) 2026-07-30

Image source: The Motley Fool. DATE Thursday, July 30, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Head of Investor Relations - Anthony DiMeoCo-Founder and Co-Chief Executive Officer - Chirag PatelCo-Founder and Co-Chief Executive Officer - Chintu PatelChief Financial Officer - Anastasios KonidarisSpecialty - Joe …

Amneal Debt Repricing Expected to Save About $12M a Year

Amneal Reports Second Quarter 2026 Financial Results

Amneal Pharmaceuticals reported strong second quarter 2026 financial results with net revenue up 10% to $796 million and adjusted EBITDA increasing 12% to $206 million. The company raised its full-year 2026 guidance, citing broad-based performance and confidence in its diversified portfolio, including anticipated contributions …

Amneal (AMRX) Reports Q2: Everything You Need To Know Ahead Of Earnings

Amneal (AMRX) Reports Q2: Everything You Need To Know Ahead Of Earnings Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be announcing earnings results this Thursday before market hours. Here's what to expect. Amneal beat analysts' revenue expectations last quarter, reporting revenues of $722.5 million, up …

Spotting Winners: Amneal (NASDAQ:AMRX) And Generic Pharmaceuticals Stocks In Q1

Amneal Pharmaceuticals stock hits 52-week high at 18.59 USD

Amneal Pharmaceuticals stock (AMRX) recently hit a 52-week high of $18.59, reflecting a 123.61% increase over the past year. Despite its strong performance, InvestingPro analysis suggests the stock is currently overvalued. The company also reported strong Q1 2026 results and received FDA approvals for …

Amneal Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:AMRX

Amneal Pharmaceuticals, Inc. Class A Revenue Breakdown – FWB:2DT

Amneal Pharmaceuticals, Inc. Class A (FWB:2DT) generated 2.57 billion EUR last year, with its Affordable Medicines segment being the top performer contributing 1.49 billion EUR. The primary revenue sources by region were the United States, India, and Ireland. The company's total revenue saw a …

How Investors May Respond To Amneal Pharmaceuticals (AMRX) Expanding Its Iohexol Generic Portfolio Across OMNIPAQUE Formats

Amneal Pharmaceuticals has received FDA approval for additional strengths and vial sizes of its iohexol injection, making it the first generic supplier for various OMNIPAQUE-referenced presentations. This expansion reinforces Amneal's injectable and hospital portfolio, potentially supporting its revenue and earnings forecasts, but also highlights …

Amneal Pharmaceuticals (AMRX) Stock May Be Fully Priced Following Its 4.7x Run

Amneal Pharmaceuticals (AMRX) has experienced a significant 4.7x share price increase over the last three years, leading to a valuation that appears expensive compared to industry averages. Despite recent FDA approval for its iohexol injection portfolio, the stock's current P/E ratio of 46.8x is …

ETFs Investing in Amneal Pharmaceuticals, Inc. Class A Stocks

This article lists various ETFs that include Amneal Pharmaceuticals, Inc. Class A stocks in their holdings. The data presented for each ETF includes market value, weight, issuer, management style, focus, expense ratio, assets under management (AUM), price, change percentage, relative volume, and 3-year NAV …

AMRX: Amneal Pharmaceuticals Inc - Ordinary Shares - Class A Latest Stock Price, Analysis, News and Trading Ideas

This article provides current stock information for Amneal Pharmaceuticals Inc (AMRX), including its latest stock price, market capitalization, volume, and key financial ratios. It also highlights recent news from Zacks indicating AMRX as a strong growth and momentum stock, along with discussions about other …

Macallum New Energy Limited (ASX:MNE) Drops 23.1% — Why the Market Suddenly Turned Cautious

How First-Generic OMNIPAQUE Rivals At Amneal Pharmaceuticals (AMRX) Have Changed Its Investment Story

Amneal Pharmaceuticals recently received FDA approval for additional strengths and vial sizes of its iohexol radiographic contrast injection, becoming the first generic version referencing OMNIPAQUE across these presentations. This expands Amneal's reach in a US$706 million market and supports its strategy of leaning on …

Amneal Pharmaceuticals stock hits 52-week high at 17.86 USD By Investing.com

Amneal Pharmaceuticals Inc. (AMRX) stock reached a new 52-week high of $17.86, trading at $17.87 with a market capitalization of $5.65 billion. This milestone follows a 116.75% increase over the past year, driven by strong financial performance including Q1 2026 EPS of $0.27 and …

Amneal gains FDA approval for four iohexol products

Amneal Pharmaceuticals received FDA approval for four new iohexol injection presentations, including three 350 mg iodine/mL vial sizes, expanding its generic contrast-agent portfolio. These products, targeting a $706 million U.S. market, are the first generic versions referencing OMNIPAQUE across these approved presentations. Amneal plans …

Is Amneal Pharmaceuticals (AMRX) Fairly Valued After Its Sharp Rerating?

Amneal Pharmaceuticals (AMRX) has experienced a significant rerating with strong short-term and long-term shareholder returns. While analysts consider it slightly undervalued at $18.25, a Discounted Cash Flow (DCF) model suggests a much higher fair value of $53.36, indicating potential undervaluation. The article highlights strategic …

Amneal schedules July 30 call for second-quarter 2026 results

What's Driving Amneal's 2026 Growth Outlook?

Is Amneal Pharmaceuticals (AMRX) Stock Undervalued Right Now?

Amneal Pharmaceuticals' (NASDAQ:AMRX) Solid Earnings Are Supported By Other Strong Factors

Amneal (AMRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Revised)

Assessing Amneal Pharmaceuticals (AMRX) Valuation After Strong Multi Year Returns And Recent Share Price Cooldown

Amneal Pharmaceuticals (AMRX) Q1 Earnings and Revenues Surpass Estimates

How The Amneal Pharmaceuticals (AMRX) Story Is Evolving Around 2026 Guidance And US$17 Targets

May 1 before the bell: Amneal to post quarterly results

Macallum New Energy Limited (MNE.XA) stock price, news, quote and history

Amneal Pharmaceuticals: Flattish 2026 Revenue Growth Aside, Stock Still Looks A Buy (AMRX)

Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Price Is Right But Growth Is Lacking After Shares Rocket 25%